Pharma in the Post-COVID Era Prescient’s industry snapshot points the direction of change for pharma businesses JULY 2020 Dr. Nick TurnerSenior Director COVID-19 has propelled the pharma industry onto the front pages with the desperate search for a vaccine. Below the...
Winning responses to the impact of COVID-19 Prescient’s thought leaders address major shifts in the landscape and outline near-, medium- and long-term choices facing pharma strategy leaders JUNE 2020 Dr. Debashish TalukdarGlobal Head of Advisory at Prescient...
Maximizing Insights from Virtual Conferences Content and offerings are evolving – so should your approach to maximize insights APRIL 2020 Ben Doran, MScVice President Tanya Casimiro, PhDEngagement Manager As conference organizers still have their missions to educate,...
By: Dr. Mark Little Prescient has conducted research among competitive intelligence (CI) stakeholders throughout the biopharmaceutical industry to identify the top challenges in CI and to highlight the strategic imperatives and actionable recommendations to face these...
By: Ben Doran, Katy Chun and Jesmine Cheung In this white paper, Prescient has identified three industry trends that are shaping competitive dynamics in the US market and how biopharmaceutical companies can optimize the performance of their brands. We discuss the...
By: Ben Doran, Stuart Crichton, Ben Druck and Vasiliki Patsioura.The Prescient team has prepared a white paper discussing our view on the recent advances in the CAR-T landscape. In this paper, we do not focus on the already well-documented challenges, but rather...
